key: cord-0290759-o5v4kqkc
authors: Whiteley, W.; Ip, S.; Cooper, J. A.; Bolton, T.; Keene, S.; Walker, V.; Denholm, R.; Akbari, A.; Omigie, E.; Hollings, S.; Di Angelantonio, E.; Denaxas, S.; Wood, A.; Sterne, J.; Sudlow, C.; consortium, CVD-COVID-UK
title: Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, and thrombocytopenic events: whole population cohort study in 46 million adults in England
date: 2021-08-23
journal: nan
DOI: 10.1101/2021.08.18.21262222
sha: cba3cd937cc350894a88c1610ee354a75593fb02
doc_id: 290759
cord_uid: o5v4kqkc

ABSTRACT Importance: Thromboses after the COVID-19 vaccine ChAdOx1-S have been reported. Better understanding of population-level thrombotic risks after COVID-19 vaccination is needed. Objective: Quantify associations of vaccination with ChAdOx1-S and BNT162b2 with major arterial, venous and thrombocytopenic events. Design: Cohort study based on linked electronic health records, with follow up from December 8th, 2020, to March 18th, 2021. Setting and participants: Adults registered with an NHS general practice in England and alive on December 8th, 2020. Exposures: First dose of vaccination with ChAdOx1-S and BNT162b2. Main Outcomes and Measures: Incidence rates and hazard ratios (HRs) for major arterial, venous and thrombocytopenic outcomes 1-28 and >28 days after first vaccination with ChAdOx1-S or BNT162b2 vaccine. Analyses were performed separately for ages <70 and [≥]70 years, and adjusted for age, sex, comorbidities, and social and demographic factors. Results: Of 46,162,942 adults, 21,193,814 (46%) had their first vaccination during follow-up. Adjusted HRs 1-28 days after ChAdOx1-S, compared with pre-vaccination rates, at ages <70 and [≥]70 respectively, were 0.97 (95% CI: 0.9-1.05) and 0.58 (0.53-0.63) for venous thromboses, and 0.90 (0.86-0.95) and 0.76 (0.73-0.79) for arterial thromboses. Corresponding HRs for BNT162b2 were 0.81 (0.74-0.88) and 0.57 (0.53-0.62) for venous thromboses, and 0.94 (0.90-0.99) and 0.72 (0.70-0.75) for arterial thromboses. HRs for thrombotic events were higher at younger ages for venous thromboses after ChAdOx1-S, and for arterial thromboses after both vaccines. Rates of intracranial venous thrombosis (ICVT) and thrombocytopenia in adults aged <70 years were higher 1-28 days after ChAdOx1-S (adjusted HRs 2.27, 95% CI:1.33-3.88 and 1.71, 1.35-2.16 respectively), but not after BNT162b2 (0.59, 0.24-1.45 and 1.00, 0.75-1.34) compared with pre-vaccination. The corresponding absolute excess risks of ICVT 1-28 days after ChAdOx1-S were 0.9-3 per million, varying by age and sex. Conclusions and Relevance: Increases in ICVT and thrombocytopenia after ChAdOx1-S vaccination in adults aged <70 years are small compared with its effect in reducing COVID-19 morbidity and mortality, although more precise estimates for adults <40 years are needed. For people aged [≥]70 years, rates of arterial or venous thrombotic, events were generally lower after either vaccine.

In late February 2021 several groups reported a rare syndrome of thrombosis and thrombocytopenia after vaccination against severe acute respiratory syndrome coronavirus-2 disease 2019 (COVID-19) with ChAdOx1-S (developed by Oxford-AstraZeneca). [1] [2] [3] Thromboses were found in unusual sites such as the cerebral venous sinuses, or mesenteric or portal veins. This syndrome, named 'vaccine-induced immune thrombotic thrombocytopenia' (VITT), is probably due to an autoimmune response to platelet factor 4 (PF4) in the absence of exposure to heparin. 1 Whether the risk of common thrombotic illnesses is also increased post-vaccination is uncertain, although there have been reports of post-vaccination ischaemic stroke and intracerebral haemorrhage. 1, 3, 4 Estimates of vaccine-associated excess risk based on case reports and routine reporting may be biased if diagnostic thresholds vary between vaccinated and unvaccinated individuals or there is less than population-wide coverage. In England, the National Health Service (NHS) provides almost all healthcare; therefore, linked health care records provide comprehensive, population-wide data on outcomes before and after vaccination. 5 Vaccination in England began on December 8 th 2020: the first groups vaccinated were care home residents, then those aged ≥80 years and frontline health and social care workers. Those clinically extremely vulnerable were invited alongside people aged ≥70 years, and those with other co-morbidities aged <65 alongside people aged >65 years. Consequently, vaccinated individuals are expected to have higher rates of venous and arterial events.

We conducted a cohort study using routinely collected, linked health data from multiple sources, covering almost the entire English adult population (>46 million). Associations of ChAdOx1-S and BNT162b2 (developed by Pfizer-BioNTech) with major venous and arterial events and thrombocytopenic haematological outcomes were estimated from the start of the vaccination program to mid-March 2021, before VITT surveillance was widespread.

Sensitivity analyses examined outcome events recorded as the primary or secondary reason for admission or death in hospital admissions or death records; fatal outcome events (those followed by death from any cause within 28-days); and all venous and all arterial thrombotic outcome events associated with thrombocytopenia. Effect modification by age, sex, ethnicity, medication, diabetes, deprivation and medical history was examined for all venous and all arterial thromboses.

Absolute excess risks of ICVT were estimated by applying estimated hazard ratios to incidence rates of first fatal or non-fatal events in decades of age and sex in 2019, derived from linked hospital and death records. The risks per 100,000 from December 8 th 2020 to March 18 th 2021 were: any venous thrombosis 45.3, any arterial thrombosis 189; thrombocytopenia 4.2 ( Table 1) . Risks of venous and arterial thromboses were higher in people with co-morbidities and with increasing age and deprivation, and varied substantially by ethnicity. Absolute and relative increases in risk with increasing age and deprivation were greater for arterial than for venous thromboses. The risk of venous thromboses was higher in people with prior DVT or PE, thrombophilia, or oral anticoagulant medication, while the risk of arterial thromboses was higher in people with prior stroke, MI or antiplatelet medication. The risk of thrombocytopenia increased with age and co-morbidities but varied less markedly with ethnicity and deprivation than the risk of venous or arterial thromboses.

Incidence rates of all events varied substantially pre-and post-vaccination (Table 2) . Before vaccination, the incidence rates per 100,000 per year were: all venous thromboses 141 (mostly PE and DVT), ICVT 1.97; portal vein thrombosis 1.15; any arterial thrombosis 549 (with slightly more ischaemic stroke (273) than MI (268)); any thrombocytopenia 13, with very low rates of DIC (0.12) and TTP (0.67). For each vaccine, crude incidence rates of venous and arterial thromboses, haemorrhagic stroke, mesenteric thrombus and thrombocytopenia were higher after than before vaccination in the under 70s, but lower after than before vaccination in the over 70s.

The additional confounding factors selected using backward selection were: for both sexes and age strata, previous diagnosis of cancer, number of unique diseases in the last year, surgery in the last year, obesity, liver disease; additionally for women aged . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.18.21262222 doi: medRxiv preprint <70, history of depression and total number of types of medication (by BNF chapters); additionally for men aged <70, history of SARS-CoV2 infection and thrombocytopenia; and additionally for men and women aged 70, chronic kidney disease and dementia.

Crude hazard ratios were substantially attenuated after adjusting for age, and further attenuated after adjusting for confounding factors. For example, in <70 year-olds the HRs 1-28 days post-versus pre-vaccination were attenuated from 2.81 to 2.27 for ICVT; from 4.85 to 1.71 for thrombocytopenia; and from 3.21 to 0.90 for ischaemic stroke (supplementary table 1 ).

In people aged <70 years, the fully adjusted HR for any venous thrombosis was 0.97 (95% CI:0.90-1.05) 1-28 days after ChAdOx1-S compared with before vaccination, with similar adjusted HRs for PE and DVT. Compared with before vaccination, the hazard of any venous thrombosis was lower 1-28 days after ChAdOx1-S in people aged ≥70 (adjusted HR 0.58, 95%CI:0.53-0.63) and 1-28 days after BNT162b2 (<70: HR 0.81, 0.74-0.88; 70 HR: 0.57, 0.53-0.62), with similar adjusted HRs for PE and DVT. (Figure 1 , supplementary table 1).

In people aged <70 years, adjusted HRs for ICVT were 2.27 (95%CI: 1.32-3.88) 1-28 days after ChAdOx1-S and 0.59 (0.24-1.45) 1-28 days after BNT162b2. HRs were similar in men and women. In a post-hoc analyses, in people aged <40 years, the HRs 1-28 days after vaccination were 3.73 (1.58-8.83) and 1.07 (0.33-3.48) for ChAdOx1-S and BNT162b2 respectively. The same estimates for people 40-69 years were 1.93 (1.19-2.13) and 0.74 (0.29-1.87). In people aged ≥70 years, associations of vaccination with ICVT were estimated imprecisely (<10 events for ChAdOx1-S and 8 for BNT162b2 (Figure 1, supplementary table 1 ).

Adjusted HRs for any arterial thrombosis 1-28 days after ChAdOx1-S were 0.90 (95%CI: 0.86-0.95) and 0.76 (0.73-0.79) in people aged <70 and 70 years respectively. Corresponding HRs 1-28 days after BNT162b2 were 0.94 (0.90-0.99) and 0.72 (0.70-0.75). HRs were similar for MI and ischaemic stroke, and >28 days after vaccination (Figure 2, supplementary table 1 ).

In people aged <70 years, adjusted HRs for thrombocytopenia were 1.71 (95%CI:1.35-2.16) 1-28 days and 1.69 (1.16-2.46) >28 days after ChAdOx1-S. Corresponding HRs after BNT162b2 were 1.00 (0.75-1.34) and 0.97 (0.66-1.41). For those aged ≥70 years, adjusted HRs for thrombocytopenia 1-28 days after vaccination were similar for ChAdOx1 (0.79, 95%CI: 0.56-1.10) and BNT162b2 (0.68, 0.51-0.90) (Figure 3, supplementary table 1 ).

Adjusted HRs for lower limb fracture 1-28 days after ChAdOx1-S were 0.85 (95% CI: 0.77-0.93), and 0.83 (0.78-0.89) in people aged <70 and 70 years respectively. compared with before vaccination in people aged <50 years for ChAdOx1-S but not BNT162b2. HRs for arterial thromboses were >1 1-28 days after compared with before vaccination in people aged <50 years for both ChAdOx1-S and BNT162b2. A higher proportion of venous thromboses in those aged <40 years compared with those aged ≥40 years were due to ICVT. A higher proportion of arterial thromboses at age <40 was due to stroke than at ages 40-59 and 60-69 years. Less marked trends for lower HRs in older individuals were observed for HRs >28 days after vaccination. Despite modest differences between the magnitude of HRs in subgroups defined by sex, ethnicity, prior COVID, COCP, diabetes, deprivation or history of MI, DVT or PE, anticoagulation or antiplatelet medication, HRs in all of these subgroups were consistent with lower rates of arterial or venous thromboses after vaccination with ChAdOx1-S or BNT162b2.

When using a less restrictive outcome definition (outcomes recorded as primary or secondary reason for admission), estimated HRs were consistent with those from analyses of outcomes in the primary position (supplementary figure 3) . Similarly, estimated HRs for fatal outcomes, were similar to HRs for outcomes in the primary position (supplementary figure 4). There were very few people for whom outcomes in the primary position were recorded as well as thrombocytopenia in any position in the same hospital admission or death record (after ChAdOx1-S and BNT162b respectively: ICVT 7 and 0; all arterial thromboses 47 and 58; all venous thromboses 37 and 26).

Characteristics were similar among patients who developed ICVT while unvaccinated, after ChAdOx1 and after BNT162b. Most were women (66% unvaccinated, 67% ChAdOx1, 79% BNT162b), of white ethnicity (75% unvaccinated, 92% ChAdOx1, 100% BNT162b), and had no prior co-morbidities (71% unvaccinated, 50% ChAdOx1, 50% BNT162b). Patients with post vaccination ICVT were older than those with prevaccination ICVT. Post-vaccination, no patients had a recorded history of thrombophilia, and fewer than 5% had a recorded dispensed prescription of oral contraceptive or HRT (supplementary Table 3 ).

Applying the HR for ICVT 1-28 days after ChAdOx1 to the monthly incidence of ICVT in 2019, the excess risk of ICVT in the month after vaccination with ChAdOx1 among those aged 19-30, 31-39, 40-49, 50-59 and 60-69-years was estimated to be, respectively: 0.9, 1.1, 1.5, 1.5 and 1.6 per million in men and 3.0, 2.7, 2.0, 1.6 and 1.5 per million in women.

In this cohort study, which included almost all adults alive in England at the start of the national COVID-19 vaccination programme, vaccination with ChAdOx1-S, but not BNT162b2, was associated with approximately 2-fold higher rates of ICVT and hospitalisations due to thrombocytopenia in people aged under 70 years, after adjusting for a comprehensive range of demographic characteristics and comorbidities. The corresponding absolute increases in the risk of these events were very small. ChAdOx1-S and BNT162b2 were associated with lower hazards of major vascular events after vaccination in those aged ≥70 years. Analyses stratified by age . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.18.21262222 doi: medRxiv preprint suggest that in people aged <50 years, rates of venous thromboses were higher 1-28 days after vaccination with ChAdOx1-S, and that rates of arterial thrombotic events were higher 1-28 days after vaccination with ChAdOx1-S or BNT162b2, compared with rates in unvaccinated people.

The large population analysed (including almost 10 times as many vaccinated people as any other published study) adds substantial precision to estimated associations of thromboses with vaccination, which is of particular importance for very rare events and associations in subgroups. The extensive data linkages across different healthcare settings enabled adjustment for a wide range of confounding variables. The analysed population is slightly larger than the mid-year estimate of the 2020 English population aged ≥18 (44,456,850) that excluded short-term residents and students, and modelled international migrant numbers. 10 Smaller Danish and Norwegian electronic health record studies reported a small excess of intracranial haemorrhage (2 per 100,000 1-28 days after ChAdOx1-S), cerebral venous thrombosis (3 per 100,000) and other venous thrombosis (2 per 100,000). 11 The randomised trials of ChAdOx1-S, reported no venous thrombotic events among 8597 participants who received the vaccine versus two among 8581who received placebo. 12 A Scottish study found a risk of of 1.13 (0.62-1.63) cases of idiopathic thrombocytopenic purpura per 100,000 after ChAdOx1-S. There was no clear evidence on other outcomes, although the number of post-vaccine events was small. 13 Reporting of ICVT cases to the UK Medicines and Healthcare products Regulatory Agency (MHRA) identified more cases of ICVT with thrombocytopenia after ChAdOx1-S than the present study (44 up to 31 st March 2021). 14 Healthcare systems planning to use ChAdOx1-S should balance the very small harms against the known benefits of the vaccine. For older populations, who are most vulnerable to COVID-19, we found no evidence of increased risk of any event with ChAdOx1-S. In younger populations, who have a lower morbidity and mortality due to COVID-19, other available vaccines might be prioritise, especially when the risk of COVID-19 is otherwise low.

Our study has several limitations. First, identification of exposures, covariates and outcomes relies on the accuracy of data collected during routine healthcare. Additional data on results of laboratory and radiology investigations would have improved diagnostic coding, particularly for ascertainment of thrombocytopenia. Second, people who were not registered with an NHS GP (for example the homeless, recent immigrants, those using only private healthcare and those not eligible for NHS care) or who opted out of their data being provided to NHS Digital were excluded. Third, follow up ended on March 18 th 2021, but a small number of events that occurred before this date may have been excluded because they had yet to be coded or the people affected were still in hospital. Analyses after this date will likely lead to overestimation of associations, because speciality societies recommended further investigations of mild symptoms in vaccinated populations. Fourth, our primary outcome used the primary reason for death or hospital admission, which improves the positive predictive value but may lead to an underestimation of incidence. This is necessary because historical non-incident events are frequently recorded in secondary positions. Analyses of events recorded in any position as fatal within 28 days were consistent with the primary analyses. Fifth, we did not address time-varying confounding, which can occur when factors which vary during follow up, such as admission to hospital, predict both vaccination and outcomes of interest. Sixth, comparison of adjusted and . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.18.21262222 doi: medRxiv preprint unadjusted associations suggests that studies that do not adjust for a comprehensive range of potential confounders will overestimate the thrombotic effects of vaccination. However, adjusted associations in this study may still be biased by unmeasured confounding by patient characteristics that predict both vaccination and thromboses and that are difficult to ascertain in electronic health records. Examples include general health at the time of vaccination, and people at higher risk of thromboses (e.g. with end-stage diseases). 15 There were slightly lower post-vaccination rates of the 'negative control' outcome lower limb fracture in those aged ≥70 years, which implies that this degree of unmeasured confounding may affect results for thrombotic outcomes in that age group.

Associations of vaccination with thromboses varied with age. This may be because in older people small increases in the risk of major thrombotic events after vaccination with ChAdOx1-S were more than offset by reductions in major thrombotic events (particularly PE) subsequent to COVID-19. By contrast, in younger people any increase in risk associated with ChAdOx1-S vaccine is less likely to be offset by a lower risk of COVID-associated thrombosis, because the chance of severe COVID disease is lower in younger than older individuals.

Further analyses assessing the effects of other vaccines and the effects of second doses of these vaccines on thrombotic, neurological and cardiac complications will be important to inform vaccination programs. Access to data from radiology or laboratory systems (which in the UK will rely on regional rather than national data collection systems) will allow more comprehensive case ascertainment and more granular phenotyping. Such efforts are currently underway across the UK. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.18.21262222 doi: medRxiv preprint This work uses data provided by patients and collected by the NHS as part of their care and support. We would also like to acknowledge all data providers who make anonymised data available for research.

Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication

None CONTRIBITIONS WW chaired the writing committee. WW, CS, JS and AW conceived the idea, and prepared the protocol and drafted the manuscript. SI, JAC, SK, VW, TB, RD and JS wrote the analytic code. VW, JAC, SK and SI prepared analytic code for open access publication. SI, VW and TB prepared the tables and figures. EO and SH prepared data from NHS Digital. SD, SK and WW prepared phenotype code. AW and JS designed and supervised the statistical analyses. CS is the Director of the BHF Data Science Centre and coordinated approvals for and access to data within the NHS Digital TRE. All authors commented on the protocol, analyses, and manuscript, and approved the final version before submission. All authors had full access to the study data. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.18.21262222 doi: medRxiv preprint Table 1 Numbers of patients analysed and (in parentheses) risk per 100,000 of venous and arterial events and thrombocytopenia (TCP) during follow up, overall and according to age. Table 2 Numbers of events and incidence rates pre and post first vaccination. Incidence rate per 100,000 per annum (a) ChAdOx1-S (b) BNT162b2 vaccine is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. ; Supplementary table 2 (b) Fully adjusted hazard ratios (HRs) for the association of ChAdOx1-S and BNT162b2 with arterial events 1-28 and >28 days after vaccination, within prespecified subgroups. P values for between subgroup differences were derived using Wald tests. OCP: oral contraceptive. HRT: hormone replacement therapy is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Hazard ratio (95% CI)

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Hazard ratio (95% CI)

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Hazard ratio (95% CI) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Hazard ratio (95% CI)

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Hazard ratio (95% CI)

Hazard ratio (95% CI)

Hazard ratio (95% CI)

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.18.21262222 doi: medRxiv preprint

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination